-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, ALL, antibodies, Biological, CRS, Leukemia, survivorship, Bleeding and Clotting, Diseases, neurotoxicity, Non-Biological, CAR-Ts, Combinations, Therapies, Adverse Events, chemotherapy, Non-Hodgkin Lymphoma, Pediatric, Thrombosis, Young Adult, Lymphoid Malignancies, Study Population, Thromboembolism, Clinically relevant, Quality Improvement , transplantation
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Kiyomi Morita, MD, PhD1, Hagop M. Kantarjian, MD1, Hong Fang, MD2*, Farhad Ravandi, MBBS1, Nitin Jain, MD1, Marina Konopleva, MD, PhD1, El Hussein Siba, MD2*, Feng Wang, PhD3*, Nicholas J. Short, MD1, Koichi Takahashi, MD, PhD1, Rita Khouri1*, Koji Sasaki, MD1, Courtney D. DiNardo, MD, MSc1, Tapan M. Kadia, MD1, Guillermo Garcia-Manero, MD1, Naval Daver, MD1, Guillermo Montalban Bravo, MD1, Sergej Konoplev, MD, PhD2*, Joseph D. Khoury, MD2 and Elias Jabbour, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Koji Sasaki, MD1, Hagop M. Kantarjian, MD1, Farhad Ravandi, MBBS1, Nicholas J. Short, MD1, Partow Kebriaei, MD2, Xuelin Huang, PhD3*, Nitin Jain, MD1, Marina Konopleva, MD, PhD1, Guillermo Garcia-Manero, MD1, Richard E. Champlin, MD2, Tapan M. Kadia, MD1, Koichi Takahashi, MD, PhD1, Naval Daver, MD1, Hind Rafei, MD4*, Joseph D. Khoury, MD5, Jeffrey L. Jorgensen, MD, PhD6*, Sa A Wang, MD6*, Maria R Khouri1*, Jovitta Jacob1*, Rebecca Garris, MSc1*, Susan M. O'Brien, MD7 and Elias Jabbour, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
7University of California Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA

Alan S. Wayne, MD1, Gerard Michel, MD2*, Daniel W. Lee, MD3, André Baruchel, MD4*, Sonali Chaudhury, MD5*, Patrick A. Brown, MD6, Michelle Hermiston, MD, PhD7, Joerg Krueger, MD8, Tong Shen, PhD9*, Kristy Tailford, PhD9* and Behzad Kharabi Masouleh, MD9*

1Children's Hospital Los Angeles, Los Angeles, CA
2Hôpital Pour Enfants la Timone, Marseille, France
3University of Virginia, Charlottesville, VA
4hematology and immunology department, Robert Debré Hospital, GH APHP Nord Université de Paris, Paris, France
5Lurie Children's Hospital of Chicago, Chicago, IL
6Johns Hopkins School of Medicine, Baltimore, MD
7Department of Pediatrics (Pediatric Hematology/Oncology), University of California San Francisco, San Francisco, CA
8The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
9Kite, a Gilead Company, Santa Monica, CA

Mayada Abu Shanap, MD1*, Iyad Sultan, MD2*, Amal Abu-Ghosh, MD3*, Hasan Hashem, MD4*, Nazmi Kamal, MD5* and Rawad Rihani, MBBS, MD2*

1Pediatric Department, King Hussein Cancer center (KHCC), Amman, Amman, Jordan
2Pediatric Department, King Hussein Cancer center (KHCC), Amman, Jordan
3Pediatric Department, King Hussein Cancer Center, Amman, DC, Jordan
4Department of Pediatrics, King Hussein Cancer Center, Amman, OH, Jordan
5Pathology Department, King Hussein Cancer Center, Amman, Jordan

Xian Zhang, MD1,2, Junfang Yang1,2*, Wenqian Li2*, Gailing Zhang, MD.2*, Yunchao Su2*, Yanze Shi2*, Dan Song2*, Min Zhang2*, Jiujiang He2*, Li Xu2*, Jingjing Li1,2*, Xinan Lu3*, Jianqiang Li, PhD4, Xiangqun Li5*, Zhongwei Xu6*, Ziyu Li7* and Peihua Lu, MD1,2

1Beijing Lu Daopei Institute of Hematology, Beijing, China
2Hebei Yanda Lu Daopei Hospital, Langfang, China
3Immunochina Pharmaceuticals Co., Ltd., Beijing, China
4Hebei Senlang Biotechnology, Shijiazhuang, Hebei, China
5Kecellitics Biotech Co., Ltd, Beijing, China
6Bioceltech Therapeutics Co., Ltd, Beijing, China
7Tsinghua University Medical School, Beijing, China

Koji Sasaki, MD1, Hagop M. Kantarjian, MD1, Farhad Ravandi, MBBS1, Nicholas J. Short, MD1, Partow Kebriaei, MD2, Xuelin Huang, PhD3*, Nitin Jain, MD1, Marina Konopleva, MD, PhD1, Guillermo Garcia-Manero, MD1, Richard E. Champlin, MD2, Tapan M. Kadia, MD1, Koichi Takahashi, MD, PhD1, Hind Rafei, MD4*, Sa A Wang, MD5*, Joseph D. Khoury, MD6, Jeffrey L. Jorgensen, MD, PhD5*, Maria Khouri1*, Jovitta Jacob1*, Rebecca Garris, MSc1*, Susan M. O'Brien, MD7 and Elias Jabbour, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
7University of California Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA

Catherine Hughes, PharmD1*, Valeria Bernardo, PharmD1*, Susanne Youssef, PharmD1*, James P. Hughes, PhD2*, Frank G. Keller, M.D.3, Tamara P. Miller, MD, MSc4, Sharon M. Castellino, MD, MSc3 and Glen Lew, MD5

1Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
2University of Washington School of Public Health, Seattle, WA
3Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children's Healthcare of Atlanta, Atlanta, GA
4Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children's Healthcare of Atlanta, Decatur, GA
5Aflac Cancer and Blood Disorders Center, Emory Univ. / Children's Healthcare of Atlanta, Atlanta, GA

Wendy Stock, MD MA1, Avi Leader, MD2,3*, Theodore G. Karrison, PhD4* and Wendy Stock, MD5

1Internal Medicine and Pediatrics, University of Chicago, Chicago, IL
2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
3Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
4Biological Sciences, University of Chicago, Chicago, IL
5Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

Josep-Maria Ribera1, Eduardo Cerello Chapchap, MD2*, Mireia Morgades, M.Prob.S1*, Eulàlia Genescà, PhD1*, Cristina Gil3*, Irene García-Cadenas4*, Pere Barba, MD, PhD5*, José González-Campos, MD6*, Anna Torrent1*, Teresa Bernal del Castillo, MD, PhD7*, Maria Paz Queipo De Llano, MD8*, María-Luz Amigo, MD9*, Mar Tormo, MD10, Rosa Coll, MD11*, Ferran Vall-Llovera, MD12*, Jordi Ribera, PhD1*, Maria Jose Sanchez, MD13*, Beatriz Soria, MD14*, Antonia Cladera15*, María Teresa Artola, MD16*, Antoni Garcia-Guiñon, MD17*, Alberto Giménez Conca, MD18*, Lourdes Amador Barciela, MD19*, Juana Ciudad, PhD20* and Alberto Orfao, MD, PhD20

1Hematology Department, ICO-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Universitat Autònoma de Barcelona, Badalona, Spain
2Hospital Israelita Albert Einstein, São Paulo, Brazil
3Hematology Department, Hospital General Universitario de Alicante, Alicante, Spain
4Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
5Hematology Department, Hospital Universitari Vall d'Hebron. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
6Hematology Department, Hospital Universitario Virgen del Rocio. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/CIBERONC. Universidad de Sevilla, Sevilla, Spain
7Hospital Universitario Central Asturias, ISPA, IUOPA, Oviedo, Spain
8Hospital Universitario Virgen de la Victoria, Málaga, Spain
9Hematology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain
10Hospital Clínico Universitario de Valencia, Valencia, Spain
11Hematology Department, ICO - Hospital Doctor Josep Trueta, Girona, Spain
12Hematology Department, Hospital Mutua de Terrassa, Terrassa, Spain
13Hematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
14Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
15Hematology Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain
16Hematology Department, Hospital Universitario de Donostia, Donostia, Spain
17Hospital Universitari Arnau de Vilanova, Lleida, Spain
18Section of Hematology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
19Hematology Department, Complejo Hospitalario Pontevedra, Pontevedra, Spain
20IBSAL, IBMCC, Centro de Investigación del Cáncer, CIBERONC, Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain

Jf Combariza1*, Leonardo Bautista Toloza, MD1*, M Arango2*, L Diaz2*, Claudia Agudelo Lopez, MD1*, Vladimir Avila1*, Sonia Milena Hernandez1*, Guillermo León-Basantes, MD1*, Ana Maria Madera Rojas1*, Jaime valdés-Cespedes1*, Fabián Mejia3*, Liliana Moreno3*, Rocio Orduz R3*, Jl Tovar-Bobadilla3* and Carlos Alberto Ramirez, MD1

1Hematology´s Department. Clínica Colsanitas. Keralty, BOGOTA, Colombia
2Hematology`s Department, Hospital Pablo Tobón Uribe, Medellín, Colombia
3Pathology`s Department. Clínica Colsanitas. Keralty, BOGOTA, Colombia

*signifies non-member of ASH